[China BD 2021] Allist Pharma and ArriVent enters a 150 million USD License on EGFR TKI Orelabrutinib for the potential treatment of multiple sclerosis (MS)

Announced Date: 2021-07-12 (July 12, 2021)

Asset Name: Orelabrutinib

Licensor (Seller): InnoCare Pharma (China)

Licensee (Buyer): Biogen

.

Asset Modality: Small Molecule

Asset Target: Bruton’s tyrosine kinase inhibitor (BTKi)

Potential Indication: oncology, autoimmune diseases

Current Stage: Phase 2 trial

.

Scope of Authority:

Biogen will have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan),

while InnoCare will retain exclusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). 

.

Payment Detail:

InnoCare will receive

Upfront payment of $125 million,

Development, commercial milestone payments up to $ 812.5 million.

Tiered royalties in the low to high teens on potential future net sales.

.

Link:

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis | Biogen

.

Note:

Chinese Name of “InnoCare Pharma“，诺诚健华

Chinese Name of “Orelabrutinib“ ，奥布替尼